Meta-Regression Analysis of the Impact of Medical Therapy on Long-Term Mortality in Type 2 Myocardial Infarction.

Abstract

The first approach for Type-2 myocardial infarction (T2MI) consists of the elimination of the condition determining the oxygen supply/demand mismatch. However, the long-term impact of medical therapy with beta blockers, statins, aspirin, and P2Y12 inhibitors, used in the case of Type-1 myocardial infarction has been poorly investigated and remains unclear. We, therefore, sought to assess the impact of medical therapy on 1-year mortality in patients with T2MI using a meta-regression analysis. A meta-regression analysis was performed with studies involving in patients with T2MI: 1-year all-cause mortality, rates of beta blockers, statins, aspirin, and P2Y12 inhibitors use were recorded and analyzed. After careful study selection, 8 observational studies were pooled in the analysis, including 3,756 in patients. During meta-regression analysis, a borderline correlation between rates of aspirin, P2Y12 inhibitors, and statins use and 1-year mortality (p = 0.087, p = 0.05, and p = 0.067, respectively) was found; no significant correlation was found at multivariable analysis. In conclusion, in a meta-regression analysis, no significant correlation was found between rates of use of usual drug therapy indicated for Type-1 myocardial infarction (statins, aspirin, P2Y12 inhibitors, β-blockers) and 1-year mortality in T2MI patients.

• Authors: Marco Mele, Lucia Tricarico, Riccardo Ieva, Massimo Iacoviello, Matteo Di Biase, Natale Daniele Brunetti
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 165 Pg. 33-36 (02 15 2022) ISSN: 1879-1913 [Electronic] United States
• PMID: 34895872 (Publication Type: Journal Article, Meta-Analysis)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Adrenergic beta-Antagonists
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Platelet Aggregation Inhibitors
• Purinergic P2Y Receptor Antagonists
• Aspirin

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Aspirin (therapeutic use)
• Dual Anti-Platelet Therapy
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Mortality
• Myocardial Infarction (classification, drug therapy)
• Platelet Aggregation Inhibitors (therapeutic use)
• Purinergic P2Y Receptor Antagonists (therapeutic use)
• Regression Analysis